Latest news with #NCI-designated
Associated Press
16-04-2025
- Business
- Associated Press
Clinical Trials Imaging Innovator Yunu Raises Oversubscribed Funding Round Led by Spring Mountain Capital
Investment is aimed at accelerating Yunu's pharma sponsor and site network growth. CARY, NORTH CAROLINA / ACCESS Newswire / April 16, 2025 / Yunu, provider of transformative clinical trials imaging workflow solutions, secured an investment led by Spring Mountain Capital, affirming Yunu's position as an emerging category leader and proven innovator within the clinical trial imaging market. Yunu's platform delivers next-generation trial imaging workflow and ensures fast delivery of operational and clinical insights to sponsors. 'At Spring Mountain Capital, we look to invest in only the strongest teams that have built truly transformational healthcare software solutions. Yunu solves a primary challenge for trial sponsors who need to accelerate therapy development timelines and conduct more trials, in more places. With imaging becoming an increasing obstacle for everyone involved, we are proud to invest in Yunu and believe they are best positioned to solve these issues at scale and emerge as the new technology-forward industry leader,' said Jamie Weston, Managing Director. Imaging endpoints play a critical role in more than 90% of oncology trials, informing crucial efficacy and safety decisions. However, published data reveals that imaging error rates between 25-50% at leading cancer centers can add up to $5m in unnecessary costs and 200 days of avoidable delay in Phase II trials alone1. Yunu addresses this industry-wide accuracy crisis by serving as the source data system, reducing imaging errors, and delivering results to sponsors in real-time at a lower cost. Yunu eliminates repetitive manual tasks, geographic limitations, disparate software systems, and paper processes with a single, streamlined cloud software platform that makes information accessible to anyone, anywhere. 'At Yunu, we are driving end-to-end imaging workflows that offer unprecedented flexibility, accuracy, and value to sites and sponsors alike,' said Jeff Sorenson, Co-founder & CEO of Yunu. 'We are delighted to partner with Spring Mountain Capital on this next phase of growth and welcome Jamie Weston as the newest member of our board of directors.' Today, Yunu serves as the trial imaging platform across all oncology clinical trials at more than 25% of the NCI-designated Comprehensive Cancer Centers in America and manages over 5,000 active oncology trials sponsored by over 400 pharma companies. Yunu will be demonstrating its capabilities at upcoming industry meetings, including: About Yunu Yunu provides innovative imaging workflow and data management solutions designed to optimize clinical trial processes. By integrating advanced technologies, Yunu enables life sciences organizations to streamline imaging workflows, improve accuracy, and accelerate timelines. Yunu's platform supports clinical trials across various therapeutic areas, offering scalability and flexibility for organizations of all sizes. For more information, visit and follow us on LinkedIn or X @Yunu_Inc. Media Inquiries: [email protected] About Spring Mountain Capital Spring Mountain Capital is an investment management firm that focuses on alternative asset investing. The SMC Growth equity team focuses on providing expansion capital to companies capitalizing on breakthrough innovations, paradigm shifts, or fundamental market or behavioral changes. SMC invests in two sectors of the U.S. economy undergoing the most change and with the highest growth potential: enterprise technology and healthcare companies. For more information, visit Contact Information Lindsay Fleming Chief Marketing Officer [email protected] SOURCE: Yunu press release
Associated Press
08-04-2025
- Entertainment
- Associated Press
Announcing the T.J. Martell Foundation Napa Best Cellars Wine Dinner
- The Wine and Music Industries Unite at this Exclusive Charity Event to Fight Cancer - NAPA, Calif., April 8, 2025 (SEND2PRESS NEWSWIRE) — On May 22, 2025, influential members of the wine and music industries will gather at the Culinary Institute of America at Greystone for the T.J. Martell Foundation Napa Best Cellars Dinner, a unique charity auction and dinner that unites these communities in the fight against cancer. The T.J. Martell Foundation funds high-risk, high reward cancer research that helps advance clinical trials and drug discoveries. The event honors Cristina and Lee Hudson of Hudson Vineyards in the wine industry and Shep Gordon of the music industry. This incredible evening features cuisine prepared by renowned chef Aaron Sanchez along with the culinary team at the Culinary Institute of America at Greystone. There will be intimate acoustic musical performances by G Love and Donavon Frankenreiter. The auction will feature rare wines, once-in-a-lifetime luxury travel, and exclusive experiences and collectibles in music and wine. Proceeds from the ticket sales and auction will go to the T.J. Martell Foundation to fund leading NCI-designated Comprehensive Cancer Centers in the United States, focusing on early-stage research conducted by the brightest minds in clinical and translational cancer science, leading to progressive and innovative clinical trials and drug discoveries. Join This Incredible Event and Make A Difference in the Fight Against Cancer About T.J. Martell T.J. Martell Foundation was founded in 1974 by music industry executive Tony Martell who promised his young son who was dying of cancer that he would raise $1 million for research so other kids with cancer could live longer lives. The T.J. Martell Foundation mission is to cure cancer by bringing the music community together to fund high-risk, high-reward cancer research that could lead to trailblazing advancements in early detection, screening, and treatments. The money we provide helps advance clinical trials and drug discoveries for various doctors, scientists, and hospitals. Some of the hospitals and clinics supported include the UCSF Helen Diller Family Comprehensive Cancer Center, Children's Hospital Los Angeles, City of Hope, Memorial Sloan Kettering Cancer Center, and Mount Sinai Tisch Cancer Center. Social: TJ Martell Foundation NEWS SOURCE: T.J. Martell Foundation Keywords: Wines and Vineyards, Culinary Institute of America at Greystone, Cancer Research, wine, food, philanthropy, aaron sanchez, tj martell foundation, domaine carneros, shep gordon, g love, donovan frankenreiter, hudson napa valley, lee hudson, remi cohen, NAPA, Calif. This press release was issued on behalf of the news source (T.J. Martell Foundation) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P125392 APNF0325A
Associated Press
11-03-2025
- Health
- Associated Press
Caris Life Sciences to Highlight Research at 2025 SGO Annual Meeting on Women's Cancer
Five studies, including two oral presentations, demonstrate the critical role of Caris' comprehensive molecular profiling in gynecological cancer IRVING, Texas, March 11, 2025 /PRNewswire/ -- Caris Life Sciences ® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (Caris POA) will collectively present five studies across multiple gynecological tumor types at the Society of Gynecologic Oncology's (SGO) Annual Meeting on Women's Cancer, March 14-17, 2025, in Seattle, Washington. The findings demonstrate the power of Caris' comprehensive clinico-genomic database to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment. 'Caris and our POA collaborators are proud to present five studies at this year's SGO Annual Meeting highlighting the critical role of molecular profiling and biomarkers in personalizing treatment for gynecological cancers,' said Caris EVP and Chief Medical Officer George W. Sledge, Jr., MD. 'By utilizing our comprehensive clinico-genomic database, we have improved the understanding of tumor biology and shown how specific molecular characteristics affect prognosis and treatment efficacy. This work exemplifies our dedication to advancing precision medicine and optimizing oncology treatment strategies.' Oral Presentations Oral Featured Poster Genomic and Immunohistochemical Characterization of NSMP Endometrial Cancer: A Novel Approach to Estrogen Receptor Positivity Oral Featured Poster Session II: Multiple Ways to Make an IMPACT March 15: 4:23-4:26 PM PST Posters GPR171, a Prognostic Marker of Improved Survival in Cervix Cancer – A Deep South Consortium in Oncology (DSCO) Project Poster Session | March 16, 2:00 – 3:30 PM PST Comparison of Breast and Gastric HER2 Immunohistochemistry (IHC) Scoring Criteria in the Assessment of Endometrial Carcinoma Poster Session | March 16, 2:00 – 3:30 PM PST Poster and abstract summaries highlighting this research will be available onsite at Caris' booth #416. The full abstracts will be available on the Caris website following the presentation. The Caris POA includes 96 cancer centers, academic institutions, research consortia and healthcare systems, including 47 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research. Caris and POA members work together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. About Caris Life Sciences Caris Life Sciences® (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multimodal database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides a differentiated platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition, and we value our employees as much as we do our patients. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. To learn more, please visit 214.294.5606
